In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS), with a price target of $27. The company’s shares closed last Monday at $11.60.
Yang commented:
“We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%).”
According to TipRanks.com, Yang is a 3-star analyst with an average return of 2.0% and a 37.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals Inc with a $22.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.98 and a one-year low of $6.85. Currently, Xeris Pharmaceuticals Inc has an average volume of 162K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.